SELVAS Healthcare, Inc (208370) Fair Value & Analysis
Healthcare · KR · Market cap 84.7B KRW
Fair value as of: Jun 24, 2026
Analysis
SELVAS Healthcare, Inc (208370) currently trades at 2,825 KRW, while our model-based Fair Value estimate is 2,193 KRW — implying the stock looks roughly 22.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals. It also offers Braille Sense notetakers and other products for blind and visually impaired people under the HIMS brand name, as well as provides digital health products under the ACCUNIQ brand name. In addition, The company provides daisy players, handheld, and desktop magnifiers. Its products are used in hospitals, medical facilities, doctor's offices, weight loss centers, Fitness Centers, nursing homes, public health facilities, and retail locations. The company was formerly known as Jawon Medical Co., Ltd. and changed its name to SELVAS Healthcare, Inc. in September 2016. SELVAS Healthcare, Inc. was founded in 1993 and is headquartered in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is SELVAS Healthcare, Inc (208370) undervalued?
What is the fair value of 208370?
What is the quality score of 208370?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.